- IBDEI1G6 ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,23412,1,4,0)
- ;;=4^D68.318
- ;;^UTILITY(U,$J,358.3,23412,2)
- ;;=^340504
- ;;^UTILITY(U,$J,358.3,23413,0)
- ;;=Z79.01^^78^1009^14
- ;;^UTILITY(U,$J,358.3,23413,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23413,1,3,0)
- ;;=3^Long Term (Current) Use of Anticoagulants
- ;;^UTILITY(U,$J,358.3,23413,1,4,0)
- ;;=4^Z79.01
- ;;^UTILITY(U,$J,358.3,23413,2)
- ;;=^5063330
- ;;^UTILITY(U,$J,358.3,23414,0)
- ;;=Z79.02^^78^1009^15
- ;;^UTILITY(U,$J,358.3,23414,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23414,1,3,0)
- ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
- ;;^UTILITY(U,$J,358.3,23414,1,4,0)
- ;;=4^Z79.02
- ;;^UTILITY(U,$J,358.3,23414,2)
- ;;=^5063331
- ;;^UTILITY(U,$J,358.3,23415,0)
- ;;=D68.62^^78^1009^16
- ;;^UTILITY(U,$J,358.3,23415,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23415,1,3,0)
- ;;=3^Lupus Anticoagulant Syndrome
- ;;^UTILITY(U,$J,358.3,23415,1,4,0)
- ;;=4^D68.62
- ;;^UTILITY(U,$J,358.3,23415,2)
- ;;=^5002361
- ;;^UTILITY(U,$J,358.3,23416,0)
- ;;=I73.9^^78^1009^17
- ;;^UTILITY(U,$J,358.3,23416,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23416,1,3,0)
- ;;=3^Peripheral Vascular Disease,Unspec
- ;;^UTILITY(U,$J,358.3,23416,1,4,0)
- ;;=4^I73.9
- ;;^UTILITY(U,$J,358.3,23416,2)
- ;;=^184182
- ;;^UTILITY(U,$J,358.3,23417,0)
- ;;=Z86.79^^78^1009^18
- ;;^UTILITY(U,$J,358.3,23417,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23417,1,3,0)
- ;;=3^Personal Hx of Circulatory System Diseases
- ;;^UTILITY(U,$J,358.3,23417,1,4,0)
- ;;=4^Z86.79
- ;;^UTILITY(U,$J,358.3,23417,2)
- ;;=^5063479
- ;;^UTILITY(U,$J,358.3,23418,0)
- ;;=Z86.711^^78^1009^19
- ;;^UTILITY(U,$J,358.3,23418,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23418,1,3,0)
- ;;=3^Personal Hx of Pulmonary Embolism
- ;;^UTILITY(U,$J,358.3,23418,1,4,0)
- ;;=4^Z86.711
- ;;^UTILITY(U,$J,358.3,23418,2)
- ;;=^5063474
- ;;^UTILITY(U,$J,358.3,23419,0)
- ;;=Z86.718^^78^1009^20
- ;;^UTILITY(U,$J,358.3,23419,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23419,1,3,0)
- ;;=3^Personal Hx of Venous Thrombosis/Embolism
- ;;^UTILITY(U,$J,358.3,23419,1,4,0)
- ;;=4^Z86.718
- ;;^UTILITY(U,$J,358.3,23419,2)
- ;;=^5063475
- ;;^UTILITY(U,$J,358.3,23420,0)
- ;;=Z95.2^^78^1009^21
- ;;^UTILITY(U,$J,358.3,23420,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23420,1,3,0)
- ;;=3^Presence of Prosthetic Heart Valve
- ;;^UTILITY(U,$J,358.3,23420,1,4,0)
- ;;=4^Z95.2
- ;;^UTILITY(U,$J,358.3,23420,2)
- ;;=^5063670
- ;;^UTILITY(U,$J,358.3,23421,0)
- ;;=D68.59^^78^1009^22
- ;;^UTILITY(U,$J,358.3,23421,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23421,1,3,0)
- ;;=3^Primary Thrombophilia
- ;;^UTILITY(U,$J,358.3,23421,1,4,0)
- ;;=4^D68.59
- ;;^UTILITY(U,$J,358.3,23421,2)
- ;;=^5002360
- ;;^UTILITY(U,$J,358.3,23422,0)
- ;;=I26.99^^78^1009^23
- ;;^UTILITY(U,$J,358.3,23422,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23422,1,3,0)
- ;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
- ;;^UTILITY(U,$J,358.3,23422,1,4,0)
- ;;=4^I26.99
- ;;^UTILITY(U,$J,358.3,23422,2)
- ;;=^5007150
- ;;^UTILITY(U,$J,358.3,23423,0)
- ;;=I42.5^^78^1009^24
- ;;^UTILITY(U,$J,358.3,23423,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23423,1,3,0)
- ;;=3^Restrictive Cardiomyopathy
- ;;^UTILITY(U,$J,358.3,23423,1,4,0)
- ;;=4^I42.5
- ;;^UTILITY(U,$J,358.3,23423,2)
- ;;=^5007196
- ;;^UTILITY(U,$J,358.3,23424,0)
- ;;=G45.9^^78^1009^26
- ;;^UTILITY(U,$J,358.3,23424,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23424,1,3,0)
- ;;=3^Transient Cerebral Ischemic Attack,Unspec
- ;;^UTILITY(U,$J,358.3,23424,1,4,0)
- ;;=4^G45.9
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1G6 3789 printed Jan 18, 2025@03:09:17 Page 2
- IBDEI1G6 ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,23412,1,4,0)
- +2 ;;=4^D68.318
- +3 ;;^UTILITY(U,$J,358.3,23412,2)
- +4 ;;=^340504
- +5 ;;^UTILITY(U,$J,358.3,23413,0)
- +6 ;;=Z79.01^^78^1009^14
- +7 ;;^UTILITY(U,$J,358.3,23413,1,0)
- +8 ;;=^358.31IA^4^2
- +9 ;;^UTILITY(U,$J,358.3,23413,1,3,0)
- +10 ;;=3^Long Term (Current) Use of Anticoagulants
- +11 ;;^UTILITY(U,$J,358.3,23413,1,4,0)
- +12 ;;=4^Z79.01
- +13 ;;^UTILITY(U,$J,358.3,23413,2)
- +14 ;;=^5063330
- +15 ;;^UTILITY(U,$J,358.3,23414,0)
- +16 ;;=Z79.02^^78^1009^15
- +17 ;;^UTILITY(U,$J,358.3,23414,1,0)
- +18 ;;=^358.31IA^4^2
- +19 ;;^UTILITY(U,$J,358.3,23414,1,3,0)
- +20 ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
- +21 ;;^UTILITY(U,$J,358.3,23414,1,4,0)
- +22 ;;=4^Z79.02
- +23 ;;^UTILITY(U,$J,358.3,23414,2)
- +24 ;;=^5063331
- +25 ;;^UTILITY(U,$J,358.3,23415,0)
- +26 ;;=D68.62^^78^1009^16
- +27 ;;^UTILITY(U,$J,358.3,23415,1,0)
- +28 ;;=^358.31IA^4^2
- +29 ;;^UTILITY(U,$J,358.3,23415,1,3,0)
- +30 ;;=3^Lupus Anticoagulant Syndrome
- +31 ;;^UTILITY(U,$J,358.3,23415,1,4,0)
- +32 ;;=4^D68.62
- +33 ;;^UTILITY(U,$J,358.3,23415,2)
- +34 ;;=^5002361
- +35 ;;^UTILITY(U,$J,358.3,23416,0)
- +36 ;;=I73.9^^78^1009^17
- +37 ;;^UTILITY(U,$J,358.3,23416,1,0)
- +38 ;;=^358.31IA^4^2
- +39 ;;^UTILITY(U,$J,358.3,23416,1,3,0)
- +40 ;;=3^Peripheral Vascular Disease,Unspec
- +41 ;;^UTILITY(U,$J,358.3,23416,1,4,0)
- +42 ;;=4^I73.9
- +43 ;;^UTILITY(U,$J,358.3,23416,2)
- +44 ;;=^184182
- +45 ;;^UTILITY(U,$J,358.3,23417,0)
- +46 ;;=Z86.79^^78^1009^18
- +47 ;;^UTILITY(U,$J,358.3,23417,1,0)
- +48 ;;=^358.31IA^4^2
- +49 ;;^UTILITY(U,$J,358.3,23417,1,3,0)
- +50 ;;=3^Personal Hx of Circulatory System Diseases
- +51 ;;^UTILITY(U,$J,358.3,23417,1,4,0)
- +52 ;;=4^Z86.79
- +53 ;;^UTILITY(U,$J,358.3,23417,2)
- +54 ;;=^5063479
- +55 ;;^UTILITY(U,$J,358.3,23418,0)
- +56 ;;=Z86.711^^78^1009^19
- +57 ;;^UTILITY(U,$J,358.3,23418,1,0)
- +58 ;;=^358.31IA^4^2
- +59 ;;^UTILITY(U,$J,358.3,23418,1,3,0)
- +60 ;;=3^Personal Hx of Pulmonary Embolism
- +61 ;;^UTILITY(U,$J,358.3,23418,1,4,0)
- +62 ;;=4^Z86.711
- +63 ;;^UTILITY(U,$J,358.3,23418,2)
- +64 ;;=^5063474
- +65 ;;^UTILITY(U,$J,358.3,23419,0)
- +66 ;;=Z86.718^^78^1009^20
- +67 ;;^UTILITY(U,$J,358.3,23419,1,0)
- +68 ;;=^358.31IA^4^2
- +69 ;;^UTILITY(U,$J,358.3,23419,1,3,0)
- +70 ;;=3^Personal Hx of Venous Thrombosis/Embolism
- +71 ;;^UTILITY(U,$J,358.3,23419,1,4,0)
- +72 ;;=4^Z86.718
- +73 ;;^UTILITY(U,$J,358.3,23419,2)
- +74 ;;=^5063475
- +75 ;;^UTILITY(U,$J,358.3,23420,0)
- +76 ;;=Z95.2^^78^1009^21
- +77 ;;^UTILITY(U,$J,358.3,23420,1,0)
- +78 ;;=^358.31IA^4^2
- +79 ;;^UTILITY(U,$J,358.3,23420,1,3,0)
- +80 ;;=3^Presence of Prosthetic Heart Valve
- +81 ;;^UTILITY(U,$J,358.3,23420,1,4,0)
- +82 ;;=4^Z95.2
- +83 ;;^UTILITY(U,$J,358.3,23420,2)
- +84 ;;=^5063670
- +85 ;;^UTILITY(U,$J,358.3,23421,0)
- +86 ;;=D68.59^^78^1009^22
- +87 ;;^UTILITY(U,$J,358.3,23421,1,0)
- +88 ;;=^358.31IA^4^2
- +89 ;;^UTILITY(U,$J,358.3,23421,1,3,0)
- +90 ;;=3^Primary Thrombophilia
- +91 ;;^UTILITY(U,$J,358.3,23421,1,4,0)
- +92 ;;=4^D68.59
- +93 ;;^UTILITY(U,$J,358.3,23421,2)
- +94 ;;=^5002360
- +95 ;;^UTILITY(U,$J,358.3,23422,0)
- +96 ;;=I26.99^^78^1009^23
- +97 ;;^UTILITY(U,$J,358.3,23422,1,0)
- +98 ;;=^358.31IA^4^2
- +99 ;;^UTILITY(U,$J,358.3,23422,1,3,0)
- +100 ;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
- +101 ;;^UTILITY(U,$J,358.3,23422,1,4,0)
- +102 ;;=4^I26.99
- +103 ;;^UTILITY(U,$J,358.3,23422,2)
- +104 ;;=^5007150
- +105 ;;^UTILITY(U,$J,358.3,23423,0)
- +106 ;;=I42.5^^78^1009^24
- +107 ;;^UTILITY(U,$J,358.3,23423,1,0)
- +108 ;;=^358.31IA^4^2
- +109 ;;^UTILITY(U,$J,358.3,23423,1,3,0)
- +110 ;;=3^Restrictive Cardiomyopathy
- +111 ;;^UTILITY(U,$J,358.3,23423,1,4,0)
- +112 ;;=4^I42.5
- +113 ;;^UTILITY(U,$J,358.3,23423,2)
- +114 ;;=^5007196
- +115 ;;^UTILITY(U,$J,358.3,23424,0)
- +116 ;;=G45.9^^78^1009^26
- +117 ;;^UTILITY(U,$J,358.3,23424,1,0)
- +118 ;;=^358.31IA^4^2
- +119 ;;^UTILITY(U,$J,358.3,23424,1,3,0)
- +120 ;;=3^Transient Cerebral Ischemic Attack,Unspec
- +121 ;;^UTILITY(U,$J,358.3,23424,1,4,0)
- +122 ;;=4^G45.9